PinnyPeptide

B7-33 vs BPC-157

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

B7-33

Muscle Growth

Single-chain relaxin peptide analog with anti-fibrotic and cardioprotective activity.

Peptide B

BPC-157

Healing & Recovery

Gastric pentadecapeptide with broad tissue-healing properties.

Typical vial

2 mg

Typical dose

1000-2000 mcg

Half-life

~2-3 hours

FDA status

Not FDA approved.

Typical vial

5 mg

Typical dose

250-500 mcg

Half-life

~4 hours (estimated from animal pharmacokinetic data)

FDA status

Not FDA approved for human use. FDA issued a warning letter …

B7-33 effects

  • Anti-fibrotic action in heart, lung, kidney tissue
  • Activates RXFP1 receptor via cGMP signaling arm
  • Vasodilatory effects
  • May support tissue remodeling and scar prevention
  • Reduces collagen deposition in injury models

BPC-157 effects

  • Accelerates tendon, ligament, and muscle healing
  • Protects and heals the gastrointestinal lining
  • Promotes angiogenesis and new blood vessel formation
  • Reduces inflammation via nitric oxide modulation
  • Exhibits neuroprotective properties
  • Upregulates growth hormone receptor expression in fibroblasts

B7-33 side effects

  • Human safety data essentially absent
  • Theoretical: hypotension from vasodilation
  • Injection-site reactions
  • Possible effect on uterine / cervical tissue (relaxin family)

BPC-157 side effects

  • Nausea at higher doses
  • Dizziness or lightheadedness
  • Injection site redness or irritation
  • Headache

B7-33 dosing ranges

Research / anti-fibrotic

1-2 mg · Daily (SubQ or IV in preclinical work) · Per research protocol

BPC-157 dosing ranges

General tissue repair

250-500 mcg · Once or twice daily · 4-6 weeks

Gut healing

250-500 mcg · Twice daily (oral or SubQ) · 4-8 weeks

Acute injury recovery

500 mcg · Twice daily near injury site · 2-4 weeks

Full B7-33 guide → Full BPC-157 guide →

B7-33 vs BPC-157 — common questions

What is the difference between B7-33 and BPC-157?

B7-33: Single-chain relaxin peptide analog with anti-fibrotic and cardioprotective activity. Typical dose 1000-2000 mcg. BPC-157: Gastric pentadecapeptide with broad tissue-healing properties. Typical dose 250-500 mcg. Both fall under the Muscle Growth and Healing & Recovery categories.

Can you stack B7-33 and BPC-157?

Stacking B7-33 with BPC-157 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, B7-33 or BPC-157?

B7-33 is typically dosed: Daily (SubQ or IV in preclinical work) for Research / anti-fibrotic. BPC-157 is typically dosed: Once or twice daily for General tissue repair; Twice daily (oral or SubQ) for Gut healing; Twice daily near injury site for Acute injury recovery.

Are B7-33 and BPC-157 FDA approved?

B7-33: Not FDA approved. BPC-157: Not FDA approved for human use. FDA issued a warning letter in 2024 regarding compounded BPC-157 products.

Related peptide comparisons

ace-031 vs b7-33ara-290 vs b7-33b7-33 vs follistatinb7-33 vs gdf-8-95b7-33 vs igf-1-lr3ara-290 vs bpc-157

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free